You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,249,222


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,249,222
Title:Anti-EPHB4 antibodies and methods using same
Abstract: The invention provides anti-EphB4 antibodies, and compositions comprising and methods of using these antibodies.
Inventor(s): Wu; Yan (Foster City, CA), Yan; Minhong (Foster City, CA)
Assignee: Genentech, Inc. (South San Francisco, CA)
Application Number:13/349,503
Patent Claims:1. A method of inhibiting angiogenesis comprising administration of an effective amount of an anti-EphB4 antibody to a subject in need of such treatment, wherein the anti-EphrinB4 antibody comprises six hypervariable regions (HVRs) and wherein the antibody comprises HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3, wherein each, in order, comprises SEQ ID NO:9, 11, 15, 2, 4, and 7.

2. The method of claim 1, further comprising administering to the subject an effective amount of an anti-angiogenic agent.

3. The method of claim 2, wherein the anti-angiogenic agent is administered prior to or subsequent to the administration of the anti-EphB4 antibody.

4. The method of claim 2, wherein the anti-angiogenic agent is administered concurrently with the anti-EphB4 antibody.

5. The method of claim 2, wherein the anti-angiogenic agent is an anti-VEGF antibody.

6. The method of claim 5, wherein the anti-VEGF antibody is AVASTIN.RTM. (bevacizumab).

7. The method of claim 1, further comprising administering an effective amount of a chemotherapeutic agent.

8. The method of claim 1, wherein the antibody comprises a human consensus framework sequence selected from the group consisting of SEQ ID NOs: 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, and 41.

9. The method of claim 1, wherein the antibody comprises human .kappa. subgroup consensus framework sequence selected from the group consisting of SEQ ID NOs:38, 39, 40, and 41.

10. The method of claim 1, wherein the antibody comprises a variable heavy (VH) subgroup III consensus framework sequence comprising at least a portion or all of: (a) EVQLVESGGGLVQPGGSLRLSCAAS (SEQ ID NO:46); (b) WVRQAPGKGLEWV (SEQ ID NO:47); (c) RFTISADTSKNTAYLQMNSLRAEDTAVYYC (SEQ ID NO:48); and (d) WGQGTLVTVSS (SEQ ID NO:49).

11. The method of claim 1, wherein the antibody comprises a VH subgroup III consensus framework sequence comprising RFTISRDNSKNTLYLQMNSLRAEDTAVYYC (SEQ ID NO:51).

12. The method of claim 1, wherein the anti-EphB4 antibody is conjugated to a detectable label or cytotoxic agent.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.